Total: 916

Avaliação de tecnologias de saúde e políticas informadas por evidências
Health technology assessment and evidence-informed policies

O Instituto de Saúde é uma instituição de ensino e pesquisa da Secretaria de Estado da Saúde de São Paulo, criada em 1969, que tem como missão “produzir conhecimento científico e tecnológico no campo da Saúde Coletiva e promover sua apropriação para o desenvolvimento de políticas públicas...

Effective care for high-need patients: opportunities for improving outcomes, outcomes, value, and health

Today, 1 percent of patients account for more than 20 percent of health care expenditures, and 5 percent account for nearly half of the nation’s spending on health care (Figure S-1) (Mitchell, 2016). Improving care management for this population while balancing quality and associated costs is at the fo...

In short supply: pay policy and nurse numbers

In April 2017, the House of Lords Select Committee on the Long-Term Sustainability of the NHS concluded that the biggest internal threat to the sustainability of the NHS is the lack of a comprehensive national strategy to secure the NHS and care system the workforce it needs. This briefing, and its two s...

Primary or specialist medical care: which is more equitable? A policy brief

Equity in health and equitable access to healthcare has been at the core of health policy in India. The key policy challenge has been how to make that possible? Various health insurance schemes such as the Rashtriya Swasthya Bima Yojana and Arogyasri seek to improve poor people’s access to specialist m...

Utility of social media and crowd-sourced data for pharmacovigilance: a scoping review protocol

: Adverse events associated with medications are under-reported in postmarketing surveillance systems. A systematic review of published data from 37 studies worldwide (including Canada) found the median under-reporting rate of adverse events to be 94% in spontaneous reporting systems. This scoping review...

EVIPNet Europe: situation analysis manual

Purpose: The WHO’s Evidence-informed Policy Network (EVIPNet) has supported Member States in designing, implementing and institutionalizing efforts to support evidence-informed policy-making (EIP). This experience has shown the importance of systematically and comprehensively identifying important cont...

Prevenção de acidentes domésticos no Distrito Federal
Prevention of domestic accidents in DF

Para prevenção de quedas, lesões, queimaduras e envenenamento entre crianças e adolescentes é possível realizar atividades educativas e campanhas que orientem adultos/cuidadores a respeito de medidas preventivas a serem adotadas. Essas orientações tendem a ser mais efetivas se acompanhadas de ins...

Informe de evaluación científica basada en la evidencia disponible. Condición de Salud: Espondilitis Anquilosante. Tecnología Sanitaria Evaluada: Fenilbutazona, Eurozina-re, Ciclobenzaprina, Mydriacyl, Duloxetina, Deflazacort, Pregabalina, Prednisona, Flexon, Paracetamol, Tramadol, Etoricoxib, Celecoxib, Metrotexato, Azulfidine, Secukinumab, Infliximab, Golimumab, Etanercept, Certolizumab y Adalimumab
Scientific evaluation report based on available evidence. Health Condition: Ankylosing Spondylitis. Evaluated Health Technology: Phenylbutazone, eurozine-re, cyclobenzaprine, mydriacyl, duloxetine, deflazacort, pregabalin, prednisone, flexon, paracetamol, tramadol, etoricoxib, celecoxib, methotrexate, azulfidine, secukinumab, infliximab, golimumab, etanercept, certolizumab and adalimumab

ANTECEDENTES: En el marco de la Ley Ricarte Soto (Ley N°20.850), que establece el proceso destinado a determinar los diagnósticos y tratamientos de alto costo con Sistema de Protección Financiera, se realizó el siguiente informe. La Espondilitis Anquilosante (EA) es una enfermedad inflamatoria crón...

Informe de evaluación científica basada en la evidencia disponible. Condición de Salud: Colitis Ulcerosa. Tecnología Sanitaria Evaluada: Adalimumab, Azatioprina, Golimumab, Infliximab, Mesalazina, Lansoprazol, Omeprazol, Sulfasalazina y Colestiramina
Scientific evaluation report based on the available evidence. Health Condition: Ulcerative Colitis. Evaluated Health Technology: Adalimumab, azathioprine, golimumab, infliximab, mesalazine, lansoprazole, omeprazole, sulfasalazine and colestiramine

ANTECEDENTES: En el marco de la Ley Ricarte Soto (Ley N°20.850), que establece el proceso destinado a determinar los diagnósticos y tratamientos de alto costo con Sistema de Protección Financiera, se realizó el siguiente informe. La colitis ulcerosa es una enfermedad inflamatoria crónica del colon q...

Informe de evaluación científica basada en la evidencia disponible. Condición de Salud: Esclerosis Múltiple. Tecnología Sanitaria Evaluada: Alemtuzumab, Ocrelizumab, Fampridina, Teriflunomida, Dimetilfumarato
Scientific evaluation report based on the available evidence. Health Condition: Multiple Sclerosis. Evaluated Health Technology: Alemtuzumab, Ocrelizumab, Fampridine, Teriflunomide, Dimethyl Fumarate

ANTECEDENTES: En el marco de la Ley Ricarte Soto (Ley N°20.850), que establece el proceso destinado a determinar los diagnósticos y tratamientos de alto costo con Sistema de Protección Financiera, se realizó el siguiente informe. La Esclerosis Múltiple (EM) afecta principalmente en forma recurrente ...